Our team is looking to improve the health of older cancer survivors after they have completed cancer treatment. Specifically, this 12-week study looks to improve older cancer survivors' physical function and related health outcomes (muscle strength, dietary quality, health-related quality of life, self-efficacy, weight management).
-History of stage I-III breast, colorectal, and prostate cancer
-Completion of curative treatment (chemotherapy, radiation, surgery)
-Have an email address
in a High-Risk Cohort for Lung Cancer
The purpose of the study is to examine the effects of exercise on long-term smokers in reducing lung cancer risk.
- Male and females aged 55 to 79 years old
- Current or former smokers with a 20-pack year smoking history (equals 1 pack a day for 20 years, 2 packs a day for 15 years, etc) and smoked within the last 15 years
- Sedentary Lifestyle: fewer than 60 minutes of participation in moderate intensity physical activity each
- Health Status: participants must be free of severe heart, respiratory (e.g. COPD), or systemic disease that would make moderate intensity exercise participation unsafe
The purpose of this study is to understand how cancer survivors view the risks and benefits of nicotine and tobacco products.
The duration of the study will last two hours.
- At least 21 years old
- Cancer survivor
- Currently smoking combustible tobacco
- Access to an email address and a phone, tablet, or computer with internet access
- Currently using electronic nicotine delivery systems (e-cigarettes, vape pens, e-hookah, etc.) OR interested in trying them in the future
This study will examine the effect of different e-cigarettes on product appeal.
- A current e-cigarette user
- 21-24 years old
- Willing to attend a study visit
- A current smoker
- 25-50 years old
- Willing to attend a study visit
- Willing to try e-cigarettes
The purpose of this study is to learn more about how to best care for patients who have immune-related side effects and have received treatment with an immune checkpoint inhibitor.
The duration of this study is 30 days.
- Must speak English and/or Spanish
- Diagnosis of cancer (excluding non-melanoma skin cancer)
- Last immunotherapy received within 90 days of study enrollment
The long-term goal of this study is to improve decision quality and health-related outcomes for sexual gender minority (SGM) breast/chest cancer survivors. The goal is to evaluate important ways the current care model needs adjusted for SGM people, and how best to combine a socially important care model into clinical practice.
Survivors: Eligible participants will participate in a 90-minute focus group and online survey regarding your opinions about improving LGBTQ+ breast/chest cancer care.
Clinicians: Eligible participants will participate in a 30-minute interview and brief survey regarding your opinions about improving LGBTQ+ breast/chest cancer care.
Participation in this study will take no more than 1 hour and 30 minutes.
1. Self-identify as a member of the SGM community
2. Age ≥18 years at the time of signing the informed consent form
3. Breast/chest cancer survivor in active treatment or completed active treatment in the last 10 years (not including hormone therapy)
4. Be able to read and speak English
5. Have received care in the U.S.
6. Be able to participate in virtual meetings
1. Physicians, advance practice providers, nurses, psychologists, social workers, therapists, technologists, and other trained clinical professionals
2. Provide care to individuals diagnosed with breast cancer in the U.S.
3. Be able to read and speak English
4. Be able to participate in virtual meetings
To evaluate the cardio-oncology patient population’s experience with using smart-phone technology as a part of self-management with their care through features such as symptom logging and education. Eligible patients will be asked to participate in a 30-minute virtual interview and/or a 60-minute virtual design or usability session to discuss their thoughts on a mobile app for cardio-oncology patients.
- English-speaking - Prior cancer diagnosis - Currently undergoing a cancer regimen that includes a targeted, biologic, radiation, and/or immune-based therapy (ex. TKIs and/or ICIs). - No pregnant females - No prisoners
Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) treatment in cancer patients. The main purpose of this study is to evaluate the safety and efficacy of OQL011 compared to vehicle ointment in treating patients with moderate to severe VEGFRi-associated HFSR. This study will also identify an optimal dosage for Phase III study and explore the pharmacokinetics profile of OQL011 in HFSR patients.
- Patient must be age 18 years of age or older. - Patient must have a confirmed cancer diagnosis for which VEGFRi treatment is indicated, and must be currently under VEGFRi-based anti-cancer therapy with stable dosage for ≥ 1 week. - Patient on pain medications is allowed provided they have been on stable dosage in the past 1 week and is going to continue at the same dosage.
The purpose of this study is to understand breast cancer survivors use of mobile health (mHealth) apps for lifestyle behavior change - eating a healthier diet, exercising more, dealing with stress, & stopping smoking. Interviews will last approximately 60 - 90 minutes.
- You have a diagnosis of breast disease or are a breast cancer survivor.
- You are age 18 or older
- You are a female
Determine the feasibility of delivering a community-based, lifestyle weight management intervention in producing meaningful improvements in weight loss and relevant clinical and patient-reported outcomes in Breast Cancer survivors.
Female breast cancer survivor within 60 months after cessation of active treatment. Overweight/Obese (BMI > 25). Ability to understand and willing to sign a written informed consent. Willing and physically able to participate in physical activity. Obtain physician consent via primary care physician and/or treating oncologist.